A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-2658
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Third Group of the B7-Cd28 Immune Checkpoint Family: HHLA2, TMIGD2, B7x, and B7-H3

Immunological Reviews
AllergyImmunology
2017English

B7-H3, a Checkpoint Molecule, as a Target for Cancer Immunotherapy

International Journal of Biological Sciences
Applied MicrobiologyEvolutionEcologyDevelopmental BiologyCell BiologyMolecular BiologySystematicsBehaviorBiotechnology
2020English

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated With EGFR Mutational Status

Clinical Cancer Research
Cancer ResearchOncology
2016English

Ring Finger Protein 43 as a New Target for Cancer Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2004English

TNFR2 and Regulatory T Cells: Potential Immune Checkpoint Target in Cancer Immunotherapy

2019English

B7-H2 Is a Costimulatory Ligand for CD28 in Human

Immunity
Infectious DiseasesAllergyImmunology
2011English

A B7-Cd28 Family Based Signature Demonstrates Significantly Different Prognoses and Tumor Immune Landscapes in Lung Adenocarcinoma

International Journal of Cancer
Cancer ResearchOncology
2018English

ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy

Current Protein and Peptide Science
MedicineBiochemistryCell BiologyMolecular Biology
2018English

B7-H4 Expression as a Predictive Biomarker in Human Cervical Cancer Immunotherapy

International Journal of Cancer Studies & Research
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy